25 XP   0   0   10

Haemonetics Corporation
Buy, Hold or Sell?

Let's analyse Haemonetics together

PenkeI guess you are interested in Haemonetics Corporation. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Haemonetics Corporation. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Haemonetics Corporation

I send you an email if I find something interesting about Haemonetics Corporation.

Quick analysis of Haemonetics (30 sec.)










What can you expect buying and holding a share of Haemonetics? (30 sec.)

How much money do you get?

How much money do you get?
$0.55
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
$15.91
Expected worth in 1 year
$21.17
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$5.80
Return On Investment
6.1%

For what price can you sell your share?

Current Price per Share
$94.40
Expected price per share
$92.73 - $95.26
How sure are you?
50%

1. Valuation of Haemonetics (5 min.)




Live pricePrice per Share (EOD)

$94.40

Intrinsic Value Per Share

$14.34 - $32.95

Total Value Per Share

$30.25 - $48.85

2. Growth of Haemonetics (5 min.)




Is Haemonetics growing?

Current yearPrevious yearGrowGrow %
How rich?$817.9m$749.4m$68.5m8.4%

How much money is Haemonetics making?

Current yearPrevious yearGrowGrow %
Making money$115.4m$43.3m$72m62.4%
Net Profit Margin9.9%4.4%--

How much money comes from the company's main activities?

3. Financial Health of Haemonetics (5 min.)




4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  


Richest
#49 / 169

Most Revenue
#53 / 169

Most Profit
#45 / 169

What can you expect buying and holding a share of Haemonetics? (5 min.)

Welcome investor! Haemonetics's management wants to use your money to grow the business. In return you get a share of Haemonetics.

What can you expect buying and holding a share of Haemonetics?

First you should know what it really means to hold a share of Haemonetics. And how you can make/lose money.

Speculation

The Price per Share of Haemonetics is $94.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Haemonetics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Haemonetics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $15.91. Based on the TTM, the Book Value Change Per Share is $1.31 per quarter. Based on the YOY, the Book Value Change Per Share is $0.33 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.14 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Haemonetics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps2.242.4%2.242.4%0.840.9%1.431.5%0.740.8%
Usd Book Value Change Per Share1.311.4%1.311.4%0.330.3%0.370.4%0.120.1%
Usd Dividend Per Share0.140.1%0.140.1%0.000.0%0.120.1%0.060.1%
Usd Total Gains Per Share1.451.5%1.451.5%0.330.3%0.490.5%0.180.2%
Usd Price Per Share82.75-82.75-63.22-88.82-67.03-
Price to Earnings Ratio36.87-36.87-74.85-67.01-49.63-
Price-to-Total Gains Ratio57.03-57.03-192.29-23.85--20.06-
Price to Book Ratio5.20-5.20-4.33-6.61-4.84-
Price-to-Total Gains Ratio57.03-57.03-192.29-23.85--20.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share94.4
Number of shares10
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.140.12
Usd Book Value Change Per Share1.310.37
Usd Total Gains Per Share1.450.49
Gains per Quarter (10 shares)14.514.93
Gains per Year (10 shares)58.0419.73
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
15534851510
211105106103030
316158164154450
422210222205970
527263280257490
6333153383089110
73836839635103130
84442145440118150
94947351245133170
105552657050148190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%29.03.00.090.6%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%3.02.00.060.0%5.05.00.050.0%25.07.00.078.1%
Dividend per Share1.00.00.0100.0%1.00.02.033.3%3.00.02.060.0%3.00.07.030.0%5.00.027.015.6%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%3.02.00.060.0%5.05.00.050.0%25.07.00.078.1%

Fundamentals of Haemonetics

About Haemonetics Corporation

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-26 02:20:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Haemonetics Corporation.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Haemonetics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Haemonetics to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of 9.9% means that $0.10 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Haemonetics Corporation:

  • The MRQ is 9.9%. The company is making a profit. +1
  • The TTM is 9.9%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.9%TTM9.9%0.0%
TTM9.9%YOY4.4%+5.5%
TTM9.9%5Y7.4%+2.5%
5Y7.4%10Y3.8%+3.5%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ9.9%6.0%+3.9%
TTM9.9%6.5%+3.4%
YOY4.4%8.0%-3.6%
5Y7.4%7.2%+0.2%
10Y3.8%6.8%-3.0%
1.1.2. Return on Assets

Shows how efficient Haemonetics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Haemonetics to the Medical Instruments & Supplies industry mean.
  • 6.0% Return on Assets means that Haemonetics generated $0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Haemonetics Corporation:

  • The MRQ is 6.0%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 6.0%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ6.0%TTM6.0%0.0%
TTM6.0%YOY2.3%+3.6%
TTM6.0%5Y4.6%+1.4%
5Y4.6%10Y2.4%+2.2%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0%1.3%+4.7%
TTM6.0%1.3%+4.7%
YOY2.3%1.8%+0.5%
5Y4.6%2.1%+2.5%
10Y2.4%2.0%+0.4%
1.1.3. Return on Equity

Shows how efficient Haemonetics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Haemonetics to the Medical Instruments & Supplies industry mean.
  • 14.1% Return on Equity means Haemonetics generated $0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Haemonetics Corporation:

  • The MRQ is 14.1%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 14.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ14.1%TTM14.1%0.0%
TTM14.1%YOY5.8%+8.3%
TTM14.1%5Y10.4%+3.7%
5Y10.4%10Y5.3%+5.1%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ14.1%2.4%+11.7%
TTM14.1%2.7%+11.4%
YOY5.8%3.7%+2.1%
5Y10.4%3.8%+6.6%
10Y5.3%3.7%+1.6%

1.2. Operating Efficiency of Haemonetics Corporation.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Haemonetics is operating .

  • Measures how much profit Haemonetics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Haemonetics to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of 13.4% means the company generated $0.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Haemonetics Corporation:

  • The MRQ is 13.4%. The company is operating less efficient.
  • The TTM is 13.4%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ13.4%TTM13.4%0.0%
TTM13.4%YOY8.1%+5.2%
TTM13.4%5Y10.5%+2.9%
5Y10.5%10Y7.6%+2.8%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ13.4%8.1%+5.3%
TTM13.4%7.6%+5.8%
YOY8.1%10.9%-2.8%
5Y10.5%10.1%+0.4%
10Y7.6%10.5%-2.9%
1.2.2. Operating Ratio

Measures how efficient Haemonetics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 0.87 means that the operating costs are $0.87 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Haemonetics Corporation:

  • The MRQ is 0.866. The company is less efficient in keeping operating costs low.
  • The TTM is 0.866. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.866TTM0.8660.000
TTM0.866YOY0.928-0.061
TTM0.8665Y0.897-0.031
5Y0.89710Y0.924-0.027
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8661.143-0.277
TTM0.8661.168-0.302
YOY0.9281.105-0.177
5Y0.8971.097-0.200
10Y0.9241.063-0.139

1.3. Liquidity of Haemonetics Corporation.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Haemonetics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 3.06 means the company has $3.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Haemonetics Corporation:

  • The MRQ is 3.057. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.057. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.057TTM3.0570.000
TTM3.057YOY1.709+1.347
TTM3.0575Y2.414+0.643
5Y2.41410Y2.437-0.023
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0572.310+0.747
TTM3.0572.358+0.699
YOY1.7092.614-0.905
5Y2.4142.649-0.235
10Y2.4372.630-0.193
1.3.2. Quick Ratio

Measures if Haemonetics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Haemonetics to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 1.85 means the company can pay off $1.85 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Haemonetics Corporation:

  • The MRQ is 1.845. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.845. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.845TTM1.8450.000
TTM1.845YOY0.947+0.898
TTM1.8455Y1.324+0.521
5Y1.32410Y1.360-0.036
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8451.119+0.726
TTM1.8451.148+0.697
YOY0.9471.306-0.359
5Y1.3241.433-0.109
10Y1.3601.544-0.184

1.4. Solvency of Haemonetics Corporation.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Haemonetics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Haemonetics to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 0.58 means that Haemonetics assets are financed with 57.7% credit (debt) and the remaining percentage (100% - 57.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Haemonetics Corporation:

  • The MRQ is 0.577. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.577. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.577TTM0.5770.000
TTM0.577YOY0.597-0.020
TTM0.5775Y0.557+0.020
5Y0.55710Y0.492+0.065
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5770.351+0.226
TTM0.5770.357+0.220
YOY0.5970.349+0.248
5Y0.5570.359+0.198
10Y0.4920.369+0.123
1.4.2. Debt to Equity Ratio

Measures if Haemonetics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Haemonetics to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 136.5% means that company has $1.37 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Haemonetics Corporation:

  • The MRQ is 1.365. The company is able to pay all its debts with equity. +1
  • The TTM is 1.365. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.365TTM1.3650.000
TTM1.365YOY1.482-0.116
TTM1.3655Y1.280+0.085
5Y1.28010Y1.016+0.265
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3650.541+0.824
TTM1.3650.552+0.813
YOY1.4820.545+0.937
5Y1.2800.632+0.648
10Y1.0160.669+0.347

2. Market Valuation of Haemonetics Corporation

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Haemonetics generates.

  • Above 15 is considered overpriced but always compare Haemonetics to the Medical Instruments & Supplies industry mean.
  • A PE ratio of 36.87 means the investor is paying $36.87 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Haemonetics Corporation:

  • The EOD is 42.062. Based on the earnings, the company is overpriced. -1
  • The MRQ is 36.871. Based on the earnings, the company is overpriced. -1
  • The TTM is 36.871. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD42.062MRQ36.871+5.191
MRQ36.871TTM36.8710.000
TTM36.871YOY74.848-37.977
TTM36.8715Y67.005-30.134
5Y67.00510Y49.634+17.371
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD42.06214.883+27.179
MRQ36.87115.934+20.937
TTM36.87116.048+20.823
YOY74.84820.784+54.064
5Y67.00520.830+46.175
10Y49.63422.810+26.824
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Haemonetics Corporation:

  • The EOD is 29.804. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 26.126. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 26.126. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD29.804MRQ26.126+3.678
MRQ26.126TTM26.1260.000
TTM26.126YOY42.856-16.731
TTM26.1265Y62.073-35.947
5Y62.07310Y95.162-33.089
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD29.8046.933+22.871
MRQ26.1267.358+18.768
TTM26.1260.019+26.107
YOY42.8563.922+38.934
5Y62.0738.172+53.901
10Y95.1620.247+94.915
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Haemonetics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of 5.20 means the investor is paying $5.20 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Haemonetics Corporation:

  • The EOD is 5.934. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.202. Based on the equity, the company is overpriced. -1
  • The TTM is 5.202. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.934MRQ5.202+0.732
MRQ5.202TTM5.2020.000
TTM5.202YOY4.332+0.870
TTM5.2025Y6.609-1.407
5Y6.60910Y4.841+1.768
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD5.9342.405+3.529
MRQ5.2022.753+2.449
TTM5.2022.660+2.542
YOY4.3323.303+1.029
5Y6.6093.958+2.651
10Y4.8414.277+0.564
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Haemonetics Corporation.

3.1. Institutions holding Haemonetics Corporation

Institutions are holding 101.567% of the shares of Haemonetics Corporation.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Capital Research Global Investors12.84520.13726523568-99580-1.5035
2023-12-31BlackRock Inc11.8930.013260400172582684.467
2023-12-31Vanguard Group Inc10.64520.01015406309254510.473
2023-12-31Neuberger Berman Group LLC6.9530.26333531181-36600-1.0258
2023-12-31Wellington Management Company LLP6.4350.052132680831010293.19
2023-12-31State Street Corporation3.52390.00741789636481512.7649
2023-12-31Franklin Resources Inc3.33530.06771693880-505-0.0298
2023-12-31FMR Inc3.11260.01041580793-39758-2.4534
2023-12-31T. Rowe Price Investment Management,Inc.2.15080.0607109229924538228.9736
2023-12-31Geode Capital Management, LLC2.13660.00971085076514744.9801
2023-12-31Royce & Associates, LP1.90280.7632966355188051.9846
2023-12-31Dimensional Fund Advisors, Inc.1.62790.0206826731596707.779
2023-12-31BTIM Corp1.41080.4622716466-4063-0.5639
2023-12-31Amvescap Plc.1.40960.0146715868-1020-0.1423
2023-12-31Westfield Capital Management Company, LP1.40210.354971206115209827.1622
2023-12-31Fisher Asset Management, LLC1.40130.0322711667-150953-17.4994
2023-12-31Boston Partners Global Investors, Inc1.3930.08707434-24168-3.3034
2023-12-31Schroder Investment Management Group1.29330.0728656810-115131-14.9145
2023-12-31Northern Trust Corp1.23760.0097628512-11152-1.7434
2023-12-31Charles Schwab Investment Management Inc1.05280.011653469489011.6929
Total 77.16182.453639187440+486299+1.2%

3.2. Funds holding Haemonetics Corporation

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31VA CollegeAmerica Amcap 529A5.80130.2466294624151977821.4212
2024-03-31American Funds SMALLCAP World A5.60920.27842848692-322272-10.1632
2023-12-31Capital Group AMCAP Composite4.77780.25832426463-197239-7.5176
2024-03-31Neuberger Berman Genesis Inv4.07531.669720696741062185.4097
2024-02-29Vanguard Total Stock Mkt Idx Inv3.12660.00751587880-3965-0.2491
2024-03-28iShares Core S&P Mid-Cap ETF3.11330.1587158110000
2024-03-31Vanguard Small Cap Index2.55060.07511295349-12682-0.9695
2024-03-28iShares Russell 2000 ETF2.41670.16122735056000.4584
2023-12-31Vanguard Explorer Inv2.00120.40641016319-15400-1.4927
2024-03-31American Funds IS® Global Small Cap 11.64061.9156833183-58681-6.5796
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr1.49770.0617760639104541.3935
2024-02-29Franklin Growth Fund A1.45170.289273726400
2023-12-31Franklin U.S. Large Cap Gr Eq1.45170.362573726400
2024-03-31Vanguard Small Cap Growth Index Inv1.44420.1722733443-1586-0.2158
2024-01-31Fidelity Small Cap Index0.99670.156150618679521.596
2024-02-29Franklin Small Cap Growth Adv0.95621.222148560000
2023-12-31Franklin US Small Cap Growth Equity0.95621.497948560000
2024-03-31Royce Small-Cap Premier Quality0.86762.50094406195984015.7152
2024-03-31Royce Premier Invmt0.86762.50094406195984015.7152
2024-03-28iShares Russell 2000 Growth ETF0.85580.3183434607-505-0.1161
Total 46.45814.258123594092+157352+0.7%

3.3. Insider Transactions

Insiders are holding 0.764% of the shares of Haemonetics Corporation.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-12Stewart W StrongSELL22890.65
2023-09-11Anila LingamneniSELL230590
2023-07-18Josep LlorensSELL492890
2023-05-30Anila LingamneniSELL230483.33

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Haemonetics Corporation compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.3151.3150%0.329+300%0.369+256%0.119+1005%
Book Value Per Share--15.90815.9080%14.594+9%13.742+16%14.316+11%
Current Ratio--3.0573.0570%1.709+79%2.414+27%2.437+25%
Debt To Asset Ratio--0.5770.5770%0.597-3%0.557+4%0.492+17%
Debt To Equity Ratio--1.3651.3650%1.482-8%1.280+7%1.016+34%
Dividend Per Share--0.1360.1360%-+100%0.124+10%0.062+119%
Eps--2.2442.2440%0.845+166%1.431+57%0.740+203%
Free Cash Flow Per Share--3.1673.1670%1.475+115%1.783+78%1.499+111%
Free Cash Flow To Equity Per Share--1.2161.2160%1.168+4%2.067-41%1.072+13%
Gross Profit Margin--0.9380.9380%0.899+4%0.933+1%0.966-3%
Intrinsic Value_10Y_max--32.946--------
Intrinsic Value_10Y_min--14.339--------
Intrinsic Value_1Y_max--2.297--------
Intrinsic Value_1Y_min--1.499--------
Intrinsic Value_3Y_max--7.666--------
Intrinsic Value_3Y_min--4.476--------
Intrinsic Value_5Y_max--13.959--------
Intrinsic Value_5Y_min--7.402--------
Market Cap4794207840.000+11%4255005000.0004255005000.0000%3246536660.000+31%4598143128.000-7%3482281359.000+22%
Net Profit Margin--0.0990.0990%0.044+126%0.074+34%0.038+157%
Operating Margin--0.1340.1340%0.081+64%0.105+28%0.076+75%
Operating Ratio--0.8660.8660%0.928-7%0.897-3%0.924-6%
Pb Ratio5.934+12%5.2025.2020%4.332+20%6.609-21%4.841+7%
Pe Ratio42.062+12%36.87136.8710%74.848-51%67.005-45%49.634-26%
Price Per Share94.400+12%82.75082.7500%63.220+31%88.824-7%67.034+23%
Price To Free Cash Flow Ratio29.804+12%26.12626.1260%42.856-39%62.073-58%95.162-73%
Price To Total Gains Ratio65.058+12%57.02957.0290%192.287-70%23.846+139%-20.055+135%
Quick Ratio--1.8451.8450%0.947+95%1.324+39%1.360+36%
Return On Assets--0.0600.0600%0.023+156%0.046+30%0.024+151%
Return On Equity--0.1410.1410%0.058+144%0.104+36%0.053+166%
Total Gains Per Share--1.4511.4510%0.329+341%0.493+194%0.181+701%
Usd Book Value--817997000.000817997000.0000%749424000.000+9%710813600.000+15%743182100.000+10%
Usd Book Value Change Per Share--1.3151.3150%0.329+300%0.369+256%0.119+1005%
Usd Book Value Per Share--15.90815.9080%14.594+9%13.742+16%14.316+11%
Usd Dividend Per Share--0.1360.1360%-+100%0.124+10%0.062+119%
Usd Eps--2.2442.2440%0.845+166%1.431+57%0.740+203%
Usd Free Cash Flow--162867000.000162867000.0000%75754000.000+115%92033000.000+77%77961300.000+109%
Usd Free Cash Flow Per Share--3.1673.1670%1.475+115%1.783+78%1.499+111%
Usd Free Cash Flow To Equity Per Share--1.2161.2160%1.168+4%2.067-41%1.072+13%
Usd Market Cap4794207840.000+11%4255005000.0004255005000.0000%3246536660.000+31%4598143128.000-7%3482281359.000+22%
Usd Price Per Share94.400+12%82.75082.7500%63.220+31%88.824-7%67.034+23%
Usd Profit--115401000.000115401000.0000%43375000.000+166%73958000.000+56%38551900.000+199%
Usd Revenue--1168660000.0001168660000.0000%993196000.000+18%997675400.000+17%953697300.000+23%
Usd Total Gains Per Share--1.4511.4510%0.329+341%0.493+194%0.181+701%
 EOD+4 -4MRQTTM+0 -0YOY+33 -35Y+29 -710Y+31 -5

4.2. Fundamental Score

Let's check the fundamental score of Haemonetics Corporation based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1542.062
Price to Book Ratio (EOD)Between0-15.934
Net Profit Margin (MRQ)Greater than00.099
Operating Margin (MRQ)Greater than00.134
Quick Ratio (MRQ)Greater than11.845
Current Ratio (MRQ)Greater than13.057
Debt to Asset Ratio (MRQ)Less than10.577
Debt to Equity Ratio (MRQ)Less than11.365
Return on Equity (MRQ)Greater than0.150.141
Return on Assets (MRQ)Greater than0.050.060
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Haemonetics Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5076.145
Ma 20Greater thanMa 5087.289
Ma 50Greater thanMa 10082.117
Ma 100Greater thanMa 20081.747
OpenGreater thanClose94.520
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,934,825
Total Liabilities1,116,828
Total Stockholder Equity817,997
 As reported
Total Liabilities 1,116,828
Total Stockholder Equity+ 817,997
Total Assets = 1,934,825

Assets

Total Assets1,934,825
Total Current Assets769,722
Long-term Assets1,165,103
Total Current Assets
Cash And Cash Equivalents 284,466
Short-term Investments 1,110
Net Receivables 179,142
Inventory 259,379
Other Current Assets 46,735
Total Current Assets  (as reported)769,722
Total Current Assets  (calculated)770,832
+/- 1,110
Long-term Assets
Property Plant Equipment 310,885
Goodwill 466,231
Intangible Assets 275,771
Long-term Assets Other 106,975
Long-term Assets  (as reported)1,165,103
Long-term Assets  (calculated)1,159,862
+/- 5,241

Liabilities & Shareholders' Equity

Total Current Liabilities251,816
Long-term Liabilities865,012
Total Stockholder Equity817,997
Total Current Liabilities
Short-term Debt 11,784
Short Long Term Debt 11,784
Accounts payable 63,929
Other Current Liabilities 145,894
Total Current Liabilities  (as reported)251,816
Total Current Liabilities  (calculated)233,391
+/- 18,425
Long-term Liabilities
Long term Debt Total 754,102
Capital Lease Obligations Min Short Term Debt-11,784
Long-term Liabilities Other 110,910
Deferred Long Term Liability 36,195
Long-term Liabilities  (as reported)865,012
Long-term Liabilities  (calculated)889,423
+/- 24,411
Total Stockholder Equity
Common Stock504
Retained Earnings 253,168
Accumulated Other Comprehensive Income -30,381
Capital Surplus 594,706
Total Stockholder Equity (as reported)817,997
Total Stockholder Equity (calculated)817,997
+/-0
Other
Capital Stock504
Cash And Equivalents284,466
Cash and Short Term Investments 284,466
Common Stock Shares Outstanding 51,420
Common Stock Total Equity504
Current Deferred Revenue30,209
Liabilities and Stockholders Equity 1,934,825
Net Debt 481,420
Net Invested Capital 765,886
Net Tangible Assets 75,995
Net Working Capital 517,906
Property Plant and Equipment Gross 944,215
Short Long Term Debt Total 765,886



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-312004-03-312003-03-312002-03-312001-03-312000-03-311999-03-311998-03-311997-03-311996-03-311995-03-311994-03-311993-03-311992-03-311991-03-31
> Total Assets 
0
144,800
180,300
230,700
280,500
287,800
323,500
336,700
356,400
349,110
345,314
364,921
359,208
407,394
467,757
546,543
572,735
608,950
649,693
754,143
833,264
910,632
1,461,871
1,520,847
1,483,119
1,317,105
1,238,709
1,237,339
1,274,767
1,267,110
1,819,923
1,859,734
1,934,825
1,934,8251,859,7341,819,9231,267,1101,274,7671,237,3391,238,7091,317,1051,483,1191,520,8471,461,871910,632833,264754,143649,693608,950572,735546,543467,757407,394359,208364,921345,314349,110356,400336,700323,500287,800280,500230,700180,300144,8000
   > Total Current Assets 
0
78,500
95,500
130,100
157,600
158,900
167,700
191,200
231,300
209,918
219,164
232,835
223,255
281,449
343,611
418,404
403,671
359,434
382,393
373,690
448,831
526,626
596,965
629,645
567,979
487,202
510,029
521,177
576,121
603,639
693,546
756,031
769,722
769,722756,031693,546603,639576,121521,177510,029487,202567,979629,645596,965526,626448,831373,690382,393359,434403,671418,404343,611281,449223,255232,835219,164209,918231,300191,200167,700158,900157,600130,10095,50078,5000
       Cash And Cash Equivalents 
0
2,900
10,300
16,200
4,200
13,400
8,300
21,800
56,300
61,328
41,441
34,913
49,885
118,117
185,815
250,667
229,227
133,553
156,721
141,562
196,707
228,861
179,120
192,469
160,662
115,123
139,564
180,169
169,351
137,311
192,305
259,496
284,466
284,466259,496192,305137,311169,351180,169139,564115,123160,662192,469179,120228,861196,707141,562156,721133,553229,227250,667185,815118,11749,88534,91341,44161,32856,30021,8008,30013,4004,20016,20010,3002,9000
       Short-term Investments 
0
0
0
0
0
0
13,600
11,900
12,300
8,000
33,042
32,636
2,700
1,900
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,110
1,1100000000000000000001,9002,70032,63633,0428,00012,30011,90013,600000000
       Net Receivables 
0
33,400
38,800
47,500
63,300
60,300
72,200
58,900
63,000
59,140
59,842
63,743
77,913
82,640
80,719
86,901
91,832
120,252
113,598
118,684
127,166
135,464
170,111
164,961
145,827
157,093
152,683
151,226
185,027
165,207
127,555
159,376
179,142
179,142159,376127,555165,207185,027151,226152,683157,093145,827164,961170,111135,464127,166118,684113,598120,25291,83286,90180,71982,64077,91363,74359,84259,14063,00058,90072,20060,30063,30047,50038,80033,4000
       Other Current Assets 
0
11,600
16,100
25,100
30,100
28,500
32,100
48,800
52,200
29,633
5,680
2,783
2,681
1,859
23,989
26,265
20,815
40,241
35,552
33,491
40,571
45,138
63,950
74,554
50,413
28,842
40,853
28,983
27,406
30,845
51,072
44,132
46,735
46,73544,13251,07230,84527,40628,98340,85328,84250,41374,55463,95045,13840,57133,49135,55240,24120,81526,26523,9891,8592,6812,7835,68029,63352,20048,80032,10028,50030,10025,10016,10011,6000
   > Long-term Assets 
0
66,300
84,800
100,600
122,900
128,900
155,800
145,500
125,100
139,192
126,150
132,086
135,953
125,945
124,146
128,139
169,064
249,516
267,300
380,453
384,433
384,006
864,906
891,202
915,140
829,903
728,680
716,162
698,646
663,471
1,126,377
1,103,703
1,165,103
1,165,1031,103,7031,126,377663,471698,646716,162728,680829,903915,140891,202864,906384,006384,433380,453267,300249,516169,064128,139124,146125,945135,953132,086126,150139,192125,100145,500155,800128,900122,900100,60084,80066,3000
       Property Plant Equipment 
0
46,800
56,000
68,300
82,100
86,400
103,600
84,200
83,000
81,608
83,251
84,877
83,987
78,030
69,337
75,266
90,775
116,484
137,807
153,298
155,528
161,657
256,953
271,437
321,948
337,634
323,862
332,156
343,979
253,399
217,559
258,482
310,885
310,885258,482217,559253,399343,979332,156323,862337,634321,948271,437256,953161,657155,528153,298137,807116,48490,77575,26669,33778,03083,98784,87783,25181,60883,00084,200103,60086,40082,10068,30056,00046,8000
       Goodwill 
0
0
0
0
0
0
0
0
0
1,800
14,426
14,168
16,000
17,200
18,200
18,483
34,958
54,222
56,426
120,543
115,367
115,058
330,474
336,768
334,310
267,840
210,841
211,395
210,819
210,652
466,444
467,287
466,231
466,231467,287466,444210,652210,819211,395210,841267,840334,310336,768330,474115,058115,367120,54356,42654,22234,95818,48318,20017,20016,00014,16814,4261,800000000000
       Intangible Assets 
0
6,900
7,600
9,300
0
0
10,300
10,700
10,500
1,832
15,842
24,204
42,349
42,026
44,020
22,945
33,857
64,333
65,261
86,102
101,789
96,549
264,388
271,159
244,588
204,458
177,540
156,589
127,693
133,106
365,483
310,261
275,771
275,771310,261365,483133,106127,693156,589177,540204,458244,588271,159264,38896,549101,78986,10265,26164,33333,85722,94544,02042,02642,34924,20415,8421,83210,50010,70010,300009,3007,6006,9000
       Other Assets 
0
0
0
0
0
0
0
0
0
33,621
37,508
5,603
6,649
3,852
5,789
6,445
9,474
14,477
7,806
14,574
11,749
10,742
13,092
11,838
14,294
21,110
16,437
16,022
16,155
14,078
17,035
67,673
58,803
58,80367,67317,03514,07816,15516,02216,43721,11014,29411,83813,09210,74211,74914,5747,80614,4779,4746,4455,7893,8526,6495,60337,50833,621000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,291
23
1,751
1,184
3,023
7,055
3,988
3,961
4,359
0
0
0
0
00004,3593,9613,9887,0553,0231,1841,751231,29100000000000000000000
> Total Liabilities 
0
54,200
53,600
69,900
87,300
70,800
98,200
142,000
134,500
142,667
129,798
128,097
135,971
127,645
112,622
104,893
93,087
114,762
109,809
161,019
147,128
175,557
692,689
681,233
656,997
597,127
499,099
484,910
606,899
680,001
1,088,253
1,110,310
1,116,828
1,116,8281,110,3101,088,253680,001606,899484,910499,099597,127656,997681,233692,689175,557147,128161,019109,809114,76293,087104,893112,622127,645135,971128,097129,798142,667134,500142,00098,20070,80087,30069,90053,60054,2000
   > Total Current Liabilities 
0
37,500
38,500
48,600
49,100
46,400
73,600
78,400
69,100
88,475
79,447
84,098
100,375
95,843
87,922
88,116
82,017
97,677
92,863
131,105
108,671
130,744
179,798
217,815
189,092
184,712
211,179
384,703
235,759
284,298
253,495
442,266
251,816
251,816442,266253,495284,298235,759384,703211,179184,712189,092217,815179,798130,744108,671131,10592,86397,67782,01788,11687,92295,843100,37584,09879,44788,47569,10078,40073,60046,40049,10048,60038,50037,5000
       Short-term Debt 
0
8,400
3,000
4,500
8,300
3,400
19,500
17,500
6,600
32,896
22,438
31,356
39,005
32,818
26,612
26,176
22,201
6,326
695
17,062
913
894
23,150
45,630
21,522
43,471
61,022
194,259
27,666
76,980
17,016
214,148
11,784
11,784214,14817,01676,98027,666194,25961,02243,47121,52245,63023,15089491317,0626956,32622,20126,17626,61232,81839,00531,35622,43832,8966,60017,50019,5003,4008,3004,5003,0008,4000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
437,687
21,681
43,625
61,022
194,259
27,666
76,980
17,016
214,148
11,784
11,784214,14817,01676,98027,666194,25961,02243,62521,681437,68700000000000000000000000
       Accounts payable 
0
9,100
13,200
14,700
15,600
16,900
27,900
21,700
10,700
17,224
13,350
12,536
13,677
14,249
11,111
14,217
17,187
19,724
20,652
25,590
28,323
35,425
49,893
53,562
48,425
39,674
42,973
55,265
63,361
50,730
50,293
58,371
63,929
63,92958,37150,29350,73063,36155,26542,97339,67448,42553,56249,89335,42528,32325,59020,65219,72417,18714,21711,11114,24913,67712,53613,35017,22410,70021,70027,90016,90015,60014,70013,2009,1000
       Other Current Liabilities 
0
20,000
22,300
29,400
25,200
26,100
26,200
39,200
51,800
38,355
43,659
40,206
47,693
48,776
50,199
19,141
26,944
46,518
71,516
114,043
46,256
129,850
83,018
93,846
96,783
74,514
80,699
109,365
117,453
127,745
159,914
137,921
145,894
145,894137,921159,914127,745117,453109,36580,69974,51496,78393,84683,018129,85046,256114,04371,51646,51826,94419,14150,19948,77647,69340,20643,65938,35551,80039,20026,20026,10025,20029,40022,30020,0000
   > Long-term Liabilities 
0
16,700
15,100
21,300
38,200
24,400
24,600
63,600
65,400
54,192
50,351
43,999
35,596
31,802
24,700
16,777
11,070
17,085
16,946
29,914
38,457
44,813
512,891
463,418
467,905
412,415
287,920
100,207
371,140
395,703
834,758
668,044
865,012
865,012668,044834,758395,703371,140100,207287,920412,415467,905463,418512,89144,81338,45729,91416,94617,08511,07016,77724,70031,80235,59643,99950,35154,19265,40063,60024,60024,40038,20021,30015,10016,7000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,966
2,877
456,944
392,057
406,369
364,529
253,625
59,423
322,454
305,513
690,592
559,441
754,102
754,102559,441690,592305,513322,45459,423253,625364,529406,369392,057456,9442,8773,96600000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,291
23
1,751
1,184
3,023
7,055
3,988
3,961
4,359
0
0
0
0
00004,3593,9613,9887,0553,0231,1841,751231,29100000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
2,164
3,070
3,212
3,984
4,678
5,469
3,800
4,395
7,795
8,474
12,915
15,822
21,551
26,095
37,641
31,737
47,483
34,295
40,784
48,686
38,177
76,905
108,603
0
0108,60376,90538,17748,68640,78434,29547,48331,73737,64126,09521,55115,82212,9158,4747,7954,3953,8005,4694,6783,9843,2123,0702,164000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,669
23,332
29,552
29,664
32,097
21,377
12,114
6,526
19,906
10,562
43,825
28,727
36,195
36,19528,72743,82510,56219,9066,52612,11421,37732,09729,66429,55223,33218,66900000000000000000000
> Total Stockholder Equity
0
90,600
126,700
160,800
193,200
217,000
225,300
194,700
221,900
206,443
215,516
236,824
223,237
279,749
355,135
441,650
479,648
494,188
539,884
593,124
686,136
735,075
769,182
839,614
826,122
719,978
739,610
752,429
667,868
587,109
731,670
749,424
817,997
817,997749,424731,670587,109667,868752,429739,610719,978826,122839,614769,182735,075686,136593,124539,884494,188479,648441,650355,135279,749223,237236,824215,516206,443221,900194,700225,300217,000193,200160,800126,70090,6000
   Common Stock
0
0
0
0
0
0
300
300
300
300
307
315
317
326
262
268
265
256
256
255
256
253
510
520
517
509
523
523
510
503
509
511
504
504511509503510523523509517520510253256255256256265268262326317315307300300300300000000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
373,630
400,783
398,199
433,347
420,365
316,184
289,916
266,942
161,418
78,512
157,981
202,391
253,168
253,168202,391157,98178,512161,418266,942289,916316,184420,365433,347398,199400,783373,63000000000000000000000
   Accumulated Other Comprehensive Income 
0
-25,300
-34,200
-45,100
-60,900
-74,400
-12,400
-19,200
-19,600
-13,078
-17,618
-16,395
-13,486
-6,535
-699
-2,834
-199
4,803
3,283
5,905
9,541
9,110
5,433
1,410
-21,724
-35,040
-32,873
-18,991
-30,380
-45,135
-29,547
-25,954
-30,381
-30,381-25,954-29,547-45,135-30,380-18,991-32,873-35,040-21,7241,4105,4339,1109,5415,9053,2834,803-199-2,834-699-6,535-13,486-16,395-17,618-13,078-19,600-19,200-12,400-74,400-60,900-45,100-34,200-25,3000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,709
322,485
365,040
402,611
426,964
439,912
482,044
503,955
536,320
553,229
602,727
572,476
594,706
594,706572,476602,727553,229536,320503,955482,044439,912426,964402,611365,040322,485302,70900000000000000000000
   Treasury Stock0000000000000000000-164,077-165,335-115,949-89,456-85,173000000000
   Other Stockholders Equity 
0
58,900
79,200
92,700
107,300
108,700
21,700
22,800
29,400
-11,511
-1,498
-11,688
-56,565
-36,333
121,803
141,371
163,815
186,933
226,829
252,323
302,709
324,929
365,040
404,337
426,964
438,325
482,044
503,955
536,320
553,229
602,727
572,476
594,706
594,706572,476602,727553,229536,320503,955482,044438,325426,964404,337365,040324,929302,709252,323226,829186,933163,815141,371121,803-36,333-56,565-11,688-1,498-11,51129,40022,80021,700108,700107,30092,70079,20058,9000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue1,168,660
Cost of Revenue-553,563
Gross Profit615,097615,097
 
Operating Income (+$)
Gross Profit615,097
Operating Expense-459,064
Operating Income156,033156,033
 
Operating Expense (+$)
Research Development50,131
Selling General Administrative369,475
Selling And Marketing Expenses7,200
Operating Expense459,064426,806
 
Net Interest Income (+$)
Interest Income14,630
Interest Expense-14,630
Other Finance Cost-14,630
Net Interest Income-14,630
 
Pretax Income (+$)
Operating Income156,033
Net Interest Income-14,630
Other Non-Operating Income Expenses-14,630
Income Before Tax (EBT)141,403170,663
EBIT - interestExpense = 141,403
141,403
130,031
Interest Expense14,630
Earnings Before Interest and Taxes (EBIT)156,033156,033
Earnings Before Interest and Taxes (EBITDA)249,340
 
After tax Income (+$)
Income Before Tax141,403
Tax Provision-26,002
Net Income From Continuing Ops115,401115,401
Net Income115,401
Net Income Applicable To Common Shares115,401
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses459,064
Total Other Income/Expenses Net-14,63029,260
 

Technical Analysis of Haemonetics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Haemonetics. The general trend of Haemonetics is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Haemonetics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Haemonetics Corporation.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 95.26.

The bearish price targets are: 93.58 > 93.58 > 92.73.

Tweet this
Haemonetics Corporation Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Haemonetics Corporation. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Haemonetics Corporation Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Haemonetics Corporation. The current macd is 2.97980018.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Haemonetics price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Haemonetics. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Haemonetics price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Haemonetics Corporation Daily Moving Average Convergence/Divergence (MACD) ChartHaemonetics Corporation Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Haemonetics Corporation. The current adx is 32.90.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Haemonetics shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Haemonetics Corporation Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Haemonetics Corporation. The current sar is 86.06.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Haemonetics Corporation Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Haemonetics Corporation. The current rsi is 76.14. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Haemonetics Corporation Daily Relative Strength Index (RSI) ChartHaemonetics Corporation Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Haemonetics Corporation. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Haemonetics price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Haemonetics Corporation Daily Stochastic Oscillator ChartHaemonetics Corporation Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Haemonetics Corporation. The current cci is 155.59.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Haemonetics Corporation Daily Commodity Channel Index (CCI) ChartHaemonetics Corporation Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Haemonetics Corporation. The current cmo is 63.77.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Haemonetics Corporation Daily Chande Momentum Oscillator (CMO) ChartHaemonetics Corporation Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Haemonetics Corporation. The current willr is -2.63067988.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Haemonetics Corporation Daily Williams %R ChartHaemonetics Corporation Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Haemonetics Corporation.

Haemonetics Corporation Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Haemonetics Corporation. The current atr is 2.14419126.

Haemonetics Corporation Daily Average True Range (ATR) ChartHaemonetics Corporation Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Haemonetics Corporation. The current obv is 16,938,935.

Haemonetics Corporation Daily On-Balance Volume (OBV) ChartHaemonetics Corporation Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Haemonetics Corporation. The current mfi is 70.06.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Haemonetics Corporation Daily Money Flow Index (MFI) ChartHaemonetics Corporation Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Haemonetics Corporation.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-02STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Haemonetics Corporation Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Haemonetics Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5076.145
Ma 20Greater thanMa 5087.289
Ma 50Greater thanMa 10082.117
Ma 100Greater thanMa 20081.747
OpenGreater thanClose94.520
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Haemonetics with someone you think should read this too:
  • Are you bullish or bearish on Haemonetics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Haemonetics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Haemonetics Corporation

I send you an email if I find something interesting about Haemonetics Corporation.


Comments

How you think about this?

Leave a comment

Stay informed about Haemonetics Corporation.

Receive notifications about Haemonetics Corporation in your mailbox!